A Normal Metabolizer on Paper, a Poor One in Practice: Fluoxetine-Driven CYP2D6 Phenoconversion, a Slowing Heart Rate on Metoprolol and What a Genotype Report Missed
[Student Name]
University of Phoenix
PMH/502: Neuropsychiatric Pharmacology
Week 2 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Mr. D., a 58-year-old man with hypertension and coronary artery disease, takes metoprolol tartrate 50 mg twice daily. His primary care clinician started fluoxetine 20 mg for depression four weeks ago. He now reports fatigue and lightheadedness, and his pulse is 46 beats per minute. A pharmacogenomic panel ordered last year reported him as a CYP2D6 normal metabolizer. His family asks how a "normal" result could lead to this. This paper explains.
CYP2D6 and Its Substrates
Cytochrome P450 2D6 metabolizes many drugs, including metoprolol, several antidepressants and some antipsychotics. Genetic variation divides people into poor, intermediate, normal and ultrarapid metabolizers. Poor metabolizers clear CYP2D6 substrates slowly and can accumulate high levels.
What the Genotype Means
Guidelines from the Clinical Pharmacogenetics Implementation Consortium translate genotype into recommendations for drugs such as antidepressants (Bousman et al., 2023; Hicks et al., 2015). A normal metabolizer result predicts typical clearance of CYP2D6 substrates, so standard doses would be expected to produce standard levels. But the genotype describes the enzyme a person is born with, not the enzyme's activity when other drugs are present.
Phenoconversion
Klomp et al. (2020) systematically reviewed phenoconversion, the mismatch between genotype-predicted and actual metabolic phenotype, and found that concomitant use of inhibiting drugs is a major cause, with strong inhibitors able to convert genotypic normal metabolizers into phenotypic poor metabolizers. Inflammation, disease and other factors can also contribute.
His genes said normal; his prescription list said otherwise, and the prescription list was the one his heart obeyed.
Fluoxetine as a Strong Inhibitor
Fluoxetine and its metabolite norfluoxetine strongly inhibit CYP2D6. With fluoxetine on board, Mr. D.'s CYP2D6 activity falls to that of a poor metabolizer, metoprolol levels rise and beta blockade intensifies, slowing his heart rate and lowering his blood pressure. The effect built over several weeks because fluoxetine and norfluoxetine have long half-lives, which is also why stopping fluoxetine will not reverse the interaction quickly.
Why the Genotype Report Missed It
The genotype report was accurate for his genes but silent on his medications. Pharmacogenomic results must be interpreted with the current drug list; CPIC guidance and the phenoconversion literature both emphasize that concomitant inhibitors can override genotype (Klomp et al., 2020).
Immediate Management
His heart rate of 46 with symptoms requires action. I contact his primary care clinician and cardiologist. They reduce metoprolol and arrange an electrocardiogram, which shows sinus bradycardia without heart block. He is advised to avoid driving until symptoms resolve and to seek emergency care for fainting or chest pain.
Choosing a Different Antidepressant
Fluoxetine will be stopped; because of its long half-life, a taper is not usually needed, but the interaction will persist for weeks. The replacement should have minimal CYP2D6 inhibition. Sertraline, a weak inhibitor at usual doses, or escitalopram or citalopram, with little CYP2D6 inhibition, are options; citalopram's QT effects make escitalopram or sertraline preferable in a man with heart disease. Because he is a genetic normal metabolizer for CYP2C19 as well, standard dosing of these drugs is expected to be appropriate under CPIC guidance (Bousman et al., 2023).
Timing the Switch
Starting sertraline while norfluoxetine remains can raise sertraline levels modestly and carries a small risk of serotonin excess; starting at a low dose and titrating slowly manages this.
How Common Is This Interaction
Beta blockers and antidepressants are frequently prescribed together, since depression is common in people with heart disease. Metoprolol, carvedilol and propranolol are CYP2D6 substrates, and fluoxetine, paroxetine and bupropion are strong inhibitors. Clinically meaningful bradycardia or hypotension from these combinations has been reported, and many are avoidable by choosing a noninhibiting antidepressant or a beta blocker less dependent on CYP2D6, such as bisoprolol.
Other CYP2D6 Substrates to Watch
CYP2D6 also metabolizes codeine and tramadol into their active forms. In a phenoconverted poor metabolizer, codeine may provide little pain relief, and tramadol's effects shift. Some antipsychotics, such as aripiprazole and risperidone, and tricyclic antidepressants are also affected. The interaction check must include everything the patient takes, including drugs prescribed by others.
Pharmacogenomic Testing in Perspective
Pharmacogenomic testing can guide dose and drug selection for some antidepressants, and CPIC guidelines provide actionable recommendations for CYP2D6 and CYP2C19 (Bousman et al., 2023). Its value depends on correct interpretation, including current medications, which is the lesson of this case. A report stored in the chart can mislead if clinicians read it as a permanent description of how a patient handles drugs.
Documentation
I document the interaction in the allergy and interaction section of his record, noting that fluoxetine and paroxetine should be avoided with his beta blocker, so that future prescribers see the warning.
Why Weeks, Not Days
Fluoxetine's half-life is two to four days and norfluoxetine's is one to two weeks, so both the inhibition and its reversal unfold slowly. Mr. D.'s bradycardia appeared after four weeks as inhibition built, and it may take several weeks after stopping fluoxetine for CYP2D6 activity to recover. Metoprolol doses should be reassessed repeatedly during this period rather than restored immediately.
The Patient's Perspective
Mr. D. felt that he had been told his genes were fine and then was harmed anyway. I explain that his genes are indeed normal but that medicines can change how the enzyme works, and that his care team will now account for both. Clear explanation restores trust in both testing and treatment.
Blood Pressure Too
His blood pressure fell to 98/60 mm Hg, also consistent with increased beta blockade. The cardiologist will recheck both heart rate and blood pressure weekly until the fluoxetine effect wears off.
Monitoring After the Switch
His pulse and pressure will be rechecked every week for six weeks, and his depression response will be tracked with the PHQ-9 at each visit, so that the change of antidepressant does not leave his mood untreated while the interaction resolves.
Family Education
His wife learns to take his pulse and will call if it falls below 50 or he feels faint.
Choosing the Beta Blocker
If a strong CYP2D6 inhibitor were ever essential for his depression, the cardiologist could switch metoprolol to bisoprolol, which relies less on CYP2D6.
Lessons for Prescribing
Before adding any psychotropic, the full medication list should be checked for interactions at CYP2D6, CYP3A4, CYP2C19 and CYP1A2. A pharmacogenomic result should be read alongside inhibitors and inducers. And the effects of fluoxetine interactions may not appear until weeks after starting, so monitoring should continue.
Conclusion
Mr. D.'s normal CYP2D6 genotype did not protect him, because fluoxetine's strong inhibition converted him to a functional poor metabolizer, raising metoprolol levels and causing symptomatic bradycardia. A systematic review of phenoconversion and CPIC guidance both caution that genotype must be interpreted with the current drug list. Switching to an antidepressant with minimal CYP2D6 inhibition, with metoprolol adjusted and heart rate monitored, resolves the problem and illustrates why interaction checking remains essential even with genetic testing.
References
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., Brown, J. T., Bell, G. C., Leeder, J. S., Gaedigk, A., Scott, S. A., Klein, T. E., Caudle, K. E., & Bishop, J. R. (2023). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology & Therapeutics, 114(1), 51-68. https://doi.org/10.1002/cpt.2903
Hicks, J. K., Bishop, J. R., Sangkuhl, K., Müller, D. J., Ji, Y., Leckband, S. G., Leeder, J. S., Graham, R. L., Chiulli, D. L., LLerena, A., Skaar, T. C., Scott, S. A., Stingl, J. C., Klein, T. E., Caudle, K. E., & Gaedigk, A. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clinical Pharmacology & Therapeutics, 98(2), 127-134. https://doi.org/10.1002/cpt.147
Klomp, S. D., Manson, M. L., Guchelaar, H.-J., & Swen, J. J. (2020). Phenoconversion of cytochrome P450 metabolism: A systematic review. Journal of Clinical Medicine, 9(9), Article 2890. https://doi.org/10.3390/jcm9092890
How this PMH 502 Week 2 example is structured
The PMH/502 Week 2 work usually addresses pharmacokinetics, pharmacogenomics and drug interactions. This paper shows how a genetic result and a drug interaction can point in opposite directions, and why the drug a patient takes can matter as much as the genes they carry. Students search this week as PMH 502 Week 2, PMH502 Wk 2 or PMH/502 Wk 2; all three are the same assignment.
PMH/502 Week 2 questions, answered
What does PMH/502 Week 2 usually ask for?
Many sections ask students to apply pharmacokinetics, pharmacogenomics and drug interaction principles to psychotropic prescribing.
What is phenoconversion?
A mismatch between genotype and actual metabolic phenotype caused by factors such as inhibiting drugs, so that a genetic normal metabolizer behaves like a poor metabolizer.
Which antidepressants strongly inhibit CYP2D6?
Fluoxetine and paroxetine are strong CYP2D6 inhibitors; bupropion is also a strong inhibitor, while sertraline and citalopram are weaker.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.